Test Price
2,800 AED✅ Home Collection Available
COL4A3 Gene Alport Syndrome (Autosomal Recessive) Genetic Test in UAE – 2,800 AED
Executive Summary & Core Metrics
Executive Summary: This advanced genetic test utilizes Next-Generation Sequencing (NGS) to provide comprehensive analysis of the COL4A3 gene for detecting mutations causing autosomal recessive Alport syndrome. The diagnostic sensitivity is 99.9% across our ISO 9001:2015 certified processing. We fully comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning the Use of Information and Communication Technology in Health Fields. The service includes a mandatory pre-test genetic counselling session, hospital-grade home sample collection via temperature-controlled cold-chain courier, and telephonic clinical guidance after results. For direct insurance billing verification, contact via WhatsApp at +971 54 548 8731.
ISO-Accredited Processing
VIP Mobile Phlebotomy
Result Interpretation
WhatsApp: +971 54 548 8731
Test Overview & Methodology
The COL4A3 Gene Alport Syndrome (Autosomal Recessive) Genetic Test is a definitive molecular diagnostic assay that screens the entire coding region of the COL4A3 gene on chromosome 2q36.3 using Next-Generation Sequencing. This test identifies pathogenic single-nucleotide variants, small insertions/deletions, and copy-number alterations responsible for autosomal recessive Alport syndrome — a progressive disorder characterized by hematuria, sensorineural hearing loss, and ocular abnormalities.
| Feature | Our COL4A3 NGS Test | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Precision | Full gene coverage including deep intronic splice regions via NGS | Limited to selected exons only; misses deep intronic variants |
| Methodology | Next-Generation Sequencing (Illumina Platform) with 150× mean read depth | Sanger Sequencing; lower throughput and resolution |
| Turnaround Time | 3 to 4 Weeks with comprehensive clinical interpretation report | 6 to 8 Weeks for equivalent coverage |
| Variant Classification | ACMG/AMP guidelines with ClinVar cross-referencing | May lack updated classification frameworks |
| Pre-Test Genetic Counselling | Mandatory pedigree-charting session included | Often not included |
Physician Insight & Safety Protocols
"As a clinical geneticist, I emphasize that the COL4A3 NGS result is a powerful piece of the diagnostic puzzle — it must always be correlated with renal function tests, audiometry, and ophthalmological findings before reaching a definitive clinical conclusion. I urge every patient to view this genetic report not as an isolated verdict but as a roadmap that, when interpreted alongside your full clinical picture, enables the most precise and personalized management strategy. Your referring physician and our genetic counsellor are your essential partners in navigating any result with clarity and confidence."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Safety Advisory
Do not discontinue or modify any prescribed medication, including ACE inhibitors, angiotensin receptor blockers, or any nephroprotective therapy, without explicit consultation with your treating nephrologist. Genetic test results provide diagnostic clarity but do not replace ongoing clinical management decisions.
Exclusion Criteria & Emergency Red Flags
- Patients currently undergoing active chemotherapy or radiotherapy must defer sample collection until completion of treatment cycle.
- Recipients of allogeneic bone marrow transplantation within the preceding 90 days are excluded due to donor DNA interference.
- Emergency Red Flag: If you experience sudden-onset gross hematuria with flank pain, acute hearing loss, or visual disturbances, seek immediate emergency medical attention — do not wait for genetic test results.
- This test is validated for blood, extracted DNA, or one-drop blood on FTA Card specimens only; buccal swabs are not accepted for this protocol.
- Minors under 18 years require documented parental consent in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What does a positive COL4A3 genetic test result mean for me and my family?
A positive COL4A3 result confirms the presence of a pathogenic variant causative of autosomal recessive Alport syndrome, requiring both gene copies to be affected for classic disease manifestation, while carriers with only one altered copy may exhibit thin basement membrane nephropathy or remain asymptomatic. This result necessitates cascade screening of first-degree relatives, particularly siblings who have a 25% risk of being affected if both parents are carriers, and should prompt coordinated evaluation by a nephrologist, audiologist, and ophthalmologist to establish baseline organ function and guide long-term surveillance.
2. How long does the COL4A3 gene test take and how accurate is it?
The result for the COL4A3 gene test is available within 3 to 4 weeks, with a diagnostic sensitivity of 99.9% when performed in our ISO 9001:2015 certified laboratory. Every sample is processed with an average read depth exceeding 150× coverage across all COL4A3 exons, and every pathogenic variant call is independently verified through orthogonal confirmation before the final clinical report is issued and reviewed by our molecular geneticist.
3. Is pre-test genetic counselling mandatory before taking this DNA test in the UAE?
Yes, pre-test genetic counselling with a qualified clinical geneticist is mandatory under Federal Decree-Law No. 4 of 2016 on Medical Liability and is integrated into our service to draw a comprehensive pedigree chart documenting all family members affected by COL4A3-related conditions. This session ensures you fully understand autosomal recessive inheritance patterns, the implications of identifying carrier status versus affected status, potential psychosocial impacts, and the data privacy protections guaranteed under the UAE Personal Data Protection Law — all before any blood sample is collected at your home or clinic appointment.
UAE Regulatory & Data Privacy Adherence
This genetic test is conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data, including genetic information, is encrypted, stored securely, and accessed only by authorized clinical personnel. Your consent is documented and your rights to access, rectify, and erase your data are respected in accordance with UAE law. DNA Labs UAE adheres to the highest standards of data privacy and security.
Clinical & Logistical Metadata
| Test Name | COL4A3 Gene Alport Syndrome (Autosomal Recessive) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA tube), Extracted DNA, or One Drop Blood on FTA Card |
| Methodology Used | Next-Generation Sequencing (Illumina Platform) with 150× mean read depth – ISO 9001:2015 Certified Laboratory |
| ICD-10-CM Code | Q87.81 |
| LOINC Code | 20851-7 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians